Analysis of New Vitamin Projects in China/data publication

December 2014 | 18 pages | ID: A03681CFFFDEN
Guangzhou CCM Information Science & Technology Co., Ltd. (CCM)

Abstracts

Vitamin industry hot topics in 2014:

• On 19 March, 2014, BASF released a statement that its citral production line in Germany plant suffered a fire and had to close down. BASF's total citral capacity accounts for more than 60% of the global capacity, thus the fire leads to the tight supply of citral and has a huge impact on the downstream of vitamin A, fragrance and flavor, vitamin E and other products. Though BASF's citral resumed production in April, domestic supply situation didn't change.
• In June 2014, Zhejiang Garden Biochemical High-tech Stock Co., Ltd. declared to suspend the production of cholesterol for its expansion project, which is expected to resume production at the end of 2015. In the meanwhile, Garden Biochemical stopped the quotation of cholesterol and vitamin D3 (VD3). Garden Biochemical, one of the largest manufacturers of VD3 in the world, the supply of VD3 was in short, which led to the surge of market price of VD3 since July. NF-class cholesterol is the main raw material of VD3. Though there are many cholesterol manufacturers, the cholesterol is not pure enough due to the technology restriction. Compared with others, Garden Biochemical is the one with better quality.
• On 25 Oct. 2014, Shandong Haineng Bioengineering Co., Ltd. conducted "25-hydroxyvitamin D3" press conference in International Conference Center of Jinan City, Shandong Province. Haineng Bioengineering launched 25-hydroxyvitamin D3, which means that China is expected to break monopoly on technology and market dominated by foreign countries to some extent. And it speeds up the production and efficiency of livestock and poultry breeding.

Purpose of report:

In this report, CCM has analyzed some of the most relevant domestic vitamin projects which are still under planning, in the process of construction, or recently completed in 2014. The analysis includes in-depth treatment of aspects related to industry and product background, company and project basic information, suggestion or prospect analysis.

What to report:

In this report, some of the most relevant domestic vitamin projects have been analyzed exhaustively from the following aspects:

• Products' background;
• Projects' detail information;
• Products' prospect.

Forecasts:

In the next few years, the vitamin industry in China will continue to be promising. On the whole, it’s worth investing in it.

Contents

1 OVERVIEW

2 VITAMIN E (VE)

2.1 Background
2.2 Project information
2.3 Prospect

3 VITAMIN B1 (VB1)

3.1 Background
3.2 Project information
3.3 Prospect

4 VITAMIN B3 (VB3)

4.1 Background
4.2 Project information
4.3 Prospect

5 VITAMIN B6 (VB6)

5.1 Background
5.2 Project information
5.3 Prospect

6 VITAMIN D3 (VD3)

6.1 Background
6.2 Project information
6.3 Prospect

7 CONCLUSION

List Of Tables

LIST OF TABLES

Table 2.1-1 Existing capacity of VE in China, 2011-2013
Table 2.1-2 Major manufacturers of China's VE, 2013
Table 2.2-1 New VE projects of major enterprises in China, 2014
Table 2.2-2 Detail information of Hegno Pharmaceutical's VE project, 2014
Table 2.2-3 VE project of Fujian Haixin, 2013
Table 3.1-1 Existing capacity of VB1 in China, 2011-2013
Table 3.1-2 Major manufacturers of China's VB1, 2013
Table 4.1-1 Existing capacity of VB3 in China, 2011-2013
Table 4.1-2 Major manufacturers of China's VB3, 2013
Table 5.1-1 Existing capacity of VB6 in China, 2011-2013
Table 5.1-2 Major manufacturers of China's VB6, 2013
Table 6.1-1 Existing capacity of VD3 in China, 2011-2013
Table 6.1-2 Major manufacturers of China's VD3, 2013

COMPANIES MENTIONED

Shandong Zhenghan Biotechnology Co., Ltd., Dafeng Hegno Pharmaceutical Co., Ltd., Fujian Haixin Pharmaceutical Co., Ltd.